Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Study Assessing Long-Term Safety of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris

Next Previous
Trial Profile

An Open-Label Study Assessing Long-Term Safety of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 Feb 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Olumacostat glasaretil (Primary)
  • Indications Acne vulgaris
  • Focus Adverse reactions
  • Acronyms CLARITUDE
  • Sponsors Dermira

Most Recent Events

  • 29 May 2018 Status changed from active, no longer recruiting to completed.
  • 06 Oct 2017 Status changed from recruiting to active, no longer recruiting.
  • 05 Oct 2017 According to a Dermira media release, positive results from CLAREOS-1 and CLAREOS-2, the completion of CLARITUDE and other registration-enabling studies are required to support a potential New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for olumacostat glasaretil.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top